ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

J&J picks Emergent to make COVID-19 vaccine

by Michael McCoy
May 2, 2020 | APPEARED IN VOLUME 98, ISSUE 17

 

Johnson & Johnson has hired Emergent BioSolutions as a US manufacturing partner for its lead COVID-19 vaccine candidate. Under the pact, worth about $135 million, Emergent will make the vaccine’s active ingredient starting later this year at its facility in Baltimore. J&J also signed a deal to use capacity at Catalent’s biologic drug facility in Bloomington, Indiana. J&J has a plan to produce 1 billion doses of its adenovirus-based vaccine.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment